Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Patients with hidradenitis suppurativa at higher risk of substance use disorder

07 Sep 2018
Substance abuse among the elderly is dangerous and require special attention to address the underlying problems.

Hidradenitis suppurativa (HS) is associated with an increased risk of substance use disorder (SUD), according to a US study. Patients with HS may benefit from periodic screening for substance abuse.

SUD prevalence among patients with HS was 4.0 percent (1,315/32,625) vs 2.0 percent (195,260/9,581,640) for those without HS (p<0.001). The most common forms of substance misuse among HS patients were as follows: alcohol (47.9 percent), opioids (32.7 percent) and cannabis (29.7 percent).

Patients with vs without HS had 1.50 (95 percent CI, 1.42–1.59) times the adjusted odds of SUD. The association between HS and SUD was generally stronger among the following: patients aged 45–64 years, nonwhites, privately insured, and those without depressive or anxiety disorder.

An earlier study found that patients at higher risk for prescription opioid misuse among those with SUD histories reported more pain and impairment, symptoms of depression, and were more likely to have current SUD compared to those at lower risk for misuse. Adjusted analysis showed pain catastrophizing to be significantly associated with risk for prescription opioid misuse. [Drug Alcohol Depend 2013;127:193-199]

In the present cross-sectional analysis that assessed SUD among HS patients in the US, the authors identified adult HS patients (n=32,625) using electronic health records data drawn from a population-based sample of >50 million patients.

One limitation of the study was that SUD might not have been accurately diagnosed, the authors said.

“Patients with HS experience chronic pain and have significant physical, emotional and psychological disease impact. These patients may be at risk for substance abuse,” they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.